Form 4: Zymeworks Chief Scientific Officer Acquires Stock Options and Restricted Stock Units

Zymeworks' Chief Scientific Officer, Paul Andrew Moore, acquired 79,000 stock options and 53,000 restricted stock units on January 10, 2025.

Summary

• Paul Andrew Moore, the Chief Scientific Officer of Zymeworks Inc., has reported the acquisition of 79,000 stock options and 53,000 restricted stock units.
• The stock options have an exercise price of $13.22 and vest over a period of 4 years, with 25% vesting on the first anniversary of the grant date and the remainder vesting monthly over the following 3 years.
• The restricted stock units (RSUs) vest in three equal annual installments starting on the first anniversary of the grant date.
• Both the stock options and RSUs were acquired on January 10, 2025.

Sentiment

Score: 7

Explanation: The document reflects a routine equity grant to a key executive, which is generally a positive sign of alignment between management and shareholders. It is not a major event, but it is a positive indicator.

Positives

• The acquisition of stock options and RSUs by the Chief Scientific Officer suggests confidence in the company's future performance.
• The vesting schedules for both options and RSUs align the officer's interests with the long-term success of the company.

Industry Context

This type of equity grant is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Equity grants, including stock options and restricted stock units, are a standard component of compensation packages for executives in the biotechnology sector.
• Companies like Amgen, Regeneron, and Gilead Sciences also use similar equity-based compensation to align executive interests with shareholder value.
• The vesting schedules described are typical for these types of grants, encouraging long-term commitment from the executive.

Stakeholder Impact

• The equity grants align the Chief Scientific Officer's interests with those of shareholders, potentially leading to increased focus on long-term value creation.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Zymeworks, stock options, restricted stock units, insider trading, executive compensation, equity, vesting